{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:27:48Z","timestamp":1789244868941,"version":"build-2803163510"},"reference-count":17,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,8,20]],"date-time":"2012-08-20T00:00:00Z","timestamp":1345420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Purpose:\u2002<\/jats:bold> To evaluate safety, tolerability, and seizure outcome data during long\u2010term treatment with once\u2010daily adjunctive perampanel (up to 12\u2003mg\/day) in patients with refractory partial\u2010onset seizures.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Study 307 was an extension study for patients completing the double\u2010blind phase of three pivotal phase III trials (studies 304, 305, and 306). The study consisted of two phases: an open\u2010label treatment phase (including a 16\u2010week blinded conversion period and a planned 256\u2010week maintenance period) and a 4\u2010week follow\u2010up phase. Patients were blindly titrated during the conversion period to their individual maximum tolerated dose (maximum 12\u2003mg\/day). Adverse events (AEs) were monitored throughout the study and seizure frequency recorded. The interim data cutoff date for analyses was December 1, 2010.<\/jats:p><jats:p><jats:bold>Key Findings:\u2002<\/jats:bold> In total, 1,218 patients were enrolled in the study. At the interim cutoff date, 1,186 patients were in the safety analysis set; 1,089 (91.8%) patients had &gt;16\u2003weeks of exposure to perampanel, 580 (48.9%) patients had &gt;1\u2003year of exposure, and 19 (1.6%) patients had &gt;2\u2003years of exposure. At the interim analysis, 840 (70.8%) patients remained on perampanel treatment. The large majority of patients (n\u2003=\u20031,084 [91%]) were titrated to 10\u2003mg or 12\u2003mg\/day. Median (range) duration of exposure was 51.4 (1.1\u2013128.1) weeks. Treatment\u2010emergent AEs were reported in 87.4% of patients. The most frequent were dizziness (43.9%), somnolence (20.2%), headache (16.7%), and fatigue (12.1%). Serious AEs were reported in 13.2% of patients. In the intent\u2010to\u2010treat analysis set (n\u2003=\u20031,207), the frequency of all seizures decreased over the first 26\u2003weeks of perampanel treatment in patients with at least 26\u2003weeks of exposure to perampanel (n\u2003=\u20031,006 [83.3%]); this reduction was maintained in patients with at least 1\u2003year of exposure (n\u2003=\u2003588 [48.7%]). The overall median percent changes in seizure frequency in patients included in each 13\u2010week interval of perampanel treatment were \u221239.2% for weeks 14\u201326 (n\u2003=\u20031,114), \u221246.5% for weeks 40\u201352 (n\u2003=\u2003731), and \u221258.1% for weeks 92\u2013104 (n\u2003=\u200359). Overall responder rates in patients included in each 13\u2010week interval of perampanel treatment were 41.4% for weeks 14\u201326 (n\u2003=\u20031,114), 46.9% for weeks 40\u201352 (n\u2003=\u2003731), and 62.7% for weeks 92\u2013104 (n\u2003=\u200359). During the blinded conversion period, the reduction in seizure frequency in patients previously randomized to placebo (\u221242.4%, n\u2003=\u2003369) was similar to that in patients previously randomized to perampanel (\u221241.5%, n\u2003=\u2003817).<\/jats:p><jats:p><jats:bold>Significance:\u2002<\/jats:bold> Consistent with pivotal phase III trials, these interim results demonstrated that perampanel had a favorable tolerability profile in patients with refractory partial\u2010onset seizures over the longer term. The decrease in seizure frequency was consistent and maintained in those patients over at least 1\u2003year of perampanel exposure.<\/jats:p>","DOI":"10.1111\/j.1528-1167.2012.03648.x","type":"journal-article","created":{"date-parts":[[2012,8,20]],"date-time":"2012-08-20T15:46:03Z","timestamp":1345477563000},"page":"126-134","source":"Crossref","is-referenced-by-count":103,"title":["Perampanel, a selective, noncompetitive \u03b1\u2010amino\u20103\u2010hydroxy\u20105\u2010methyl\u20104\u2010isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial\u2010onset seizures: Interim results from phase III, extension study 307"],"prefix":"10.1111","volume":"54","author":[{"given":"Gregory L.","family":"Krauss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Perucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elinor","family":"Ben\u2010Menachem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry J.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Squillacote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Gee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Laurenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,8,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2003.54102.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90754-5"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.00992.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182635735"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03638.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02660.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03109.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2011.01588.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318254473a"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2006.11.010"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70047-3"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70215-6"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7511-11.2.56"},{"key":"e_1_2_7_15_1","first-page":"947","article-title":"AMPA receptors in epilepsy and as targets for antiepileptic drugs","volume":"79","author":"Rogawski MA","year":"1999","journal-title":"Adv Neurol"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.2174\/157015909788848857"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2008.01055.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.2002.282.1.R147"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2012.03648.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2012.03648.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T11:17:19Z","timestamp":1698664639000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2012.03648.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,20]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1111\/j.1528-1167.2012.03648.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03648.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,20]]}}}